Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options
A class action was filed against against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”), Bain Capital Investors, LLC (“Bain”) and Pfizer, Inc. (“Pfizer”) on behalf of investors that (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants’ violations of Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”); (b) held shares of Cerevel as of January 8, 2024 (the “Record Date”) and were entitled to vote on the merger of Cerevel and AbbVie Inc. (“AbbVie”) and thus were damaged by defendants’ violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain’s purchase of shares on or about October 16, 2023 and thus were damaged by Bain’s violations of Section 20A of the Exchange Act. If you would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, May 11, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE), Bain Capital Investors, LLC (“Bain”) and Pfizer, Inc. (“Pfizer”) and reminds investors of the June 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
The complaint alleges that the defendants violated federal securities laws by making false and/or misleading statements and/or failing to disclose material facts in connection with Cerevel’s October 16, 2023 secondary stock offering at $22.81, in which Cerevel’s controlling shareholder, Bain, acquired Cerevel shares while allegedly in possession of material nonpublic information regarding AbbVie’s interest in acquiring the Company. Two months later, the Company disclosed the agreement with AbbVie at a price of $45 per share resulting in a windfall for Bain. The complaint alleges that Cerevel’s January 18, 2024, Proxy statement for the AbbVie acquisition misled investors regarding the true nature and timing of the sales process and related conflicts, including that the process and October Offering were orchestrated by Bain and Pfizer in order to maximize profits and rush through a sale of the Company even if it was not in the best interest of public shareholders.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Cerevel’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Cerevel class action, go to www.faruqilaw.com/CERE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6e8a581f-1c68-4596-885c-0a64b18c9ae1
